Clinical trials of VPM1002 as a tuberculosis vaccine in newborns

March 24, 2015, Max Planck Society

The only tuberculosis vaccine currently approved, the Bacillus Calmette-Guérin (BCG) vaccine, protects children from the most severe forms of the disease in most cases but does not provide protection against the most common form, pulmonary tuberculosis in adults and children. BCG has therefore been unable to contain tuberculosis worldwide. Scientists led by Stefan Kaufmann of the Max Planck Institute for Infection Biology in Berlin are therefore working feverishly on a more effective replacement for BCG. The vaccine candidate they have developed, dubbed VPM1002, will now be tested in a large-scale phase II trial with newborns. VPM1002 is a genetically modified variant of the Bacillus Calmette-Guérin (BCG) vaccine. Moreover, another trial will test whether VPM1002 is effective in the treatment of cancer of the bladder.

BCG was developed in 1921 and has since been the only available vaccine against tuberculosis. It consists of weakened Mycobacterium bovis bacteria, the causative agent of bovine tuberculosis, which is also transmissible to humans. The vaccine primes the immune system to fend off an infection due to Mycobacterium tuberculosis bacteria, the causative agents of tuberculosis in humans.

VPM1002 is based on the BCG vaccine. The Mycobacterium bovis bacteria it contains have been genetically modified and provided with a gene that makes it easier for the vaccine to be recognized by cells of the immune system. The vaccine should be more effective at protecting vaccinees from infection with Mycobacterium tuberculosis bacteria. VPM1002 was developed by a group headed by Stefan Kaufmann, Director of the Max Planck Institute for Infection Biology. It is produced by the Serum Institute of India, the world's biggest manufacturer of vaccines in terms of volume. The company is sponsoring the development of VPM1002 in South Africa as a with the support of Vakzine Projekt Management GmbH (VPM) in Hanover.

The has already been successfully tested in newborns in two clinical phase I and one clinical phase IIa trial in Germany and South Africa. Now newborn babies of HIV-positive and HIV-negative mothers will be vaccinated with VPM1002 at four clinics in South Africa, and the protection conferred against tuberculosis will be compared with that of BCG. The first vaccination is scheduled for April 2015.

Because BCG is also used as an immunotherapeutic agent against cancer of the bladder, it is also planned to test the efficacy of VPM1002 against this form of cancer. An application for the first clinical trial with VPM1002BC for the treatment of nonmuscle invasive bladder cancer was submitted in December 2014. The SAKK 06/14 trial is being sponsored by the Swiss Working Group for Clinical Cancer Research with support by VPM. The first patient will be treated with VPM1002BC in May 2015.

Explore further: Tuberculosis vaccine being tested in Phase II trial

Related Stories

Tuberculosis vaccine being tested in Phase II trial

March 26, 2012
The only tuberculosis vaccine currently available is already over 90 years old - and is unsatisfactory in terms of its effectiveness. Although it protects young children against developing tuberculosis, it quickly loses its ...

Serum Institute of India acquires rights to German TB vaccine

July 23, 2013
Hopes are high for a new and improved tuberculosis vaccine: Serum Institute of India is planning on taking a promising vaccine - originally developed in Germany - and introducing it into the clinical setting. Studies have ...

New vaccine shows promise as stronger weapon against both tuberculosis and leprosy

August 19, 2014
In many parts of the world, leprosy and tuberculosis live side-by-side. Worldwide there are approximately 233,000 new cases of leprosy per year, with nearly all of them occurring where tuberculosis is endemic.

Common tuberculosis vaccine can be used to prevent infection as well as disease

August 5, 2014
The vaccine used to protect against tuberculosis disease (bacillus calmette-guerin or BCG) also protects against tuberculosis infection (mycobacterium) as well as protecting against progression from infection to disease, ...

New tuberculosis vaccine boosts impacts of old counterpart

October 2, 2013
A tuberculosis vaccine developed at McMaster University offers new hopes for the global fight against tuberculosis.

Recommended for you

Study identifies a key cellular mechanism that triggers pneumonia in humans

December 11, 2018
The relationship between influenza and pneumonia has long been observed by health workers. Its genetic and cellular mechanisms have now been investigated in depth by scientists in a study involving volunteers and conducted ...

Human antibody discovery could save lives from fungal killer

December 11, 2018
A new way to diagnose, treat and protect against stealth fungal infections that claim more than 1.5 million lives per year worldwide has been moved a step closer, according to research published in Nature Communications.

Dialysis patients at risk of progressive brain injury

December 10, 2018
Kidney dialysis can cause short-term 'cerebral stunning' and may be associated with progressive brain injury in those who receive the treatment for many years. For many patients with kidney failure awaiting a kidney transplant ...

Silicosis is on the rise, but is there a therapeutic target?

December 6, 2018
Researchers from the CNRS, the University of Orléans, and the company Artimmune, in collaboration with Turkish clinicians from Atatürk University, have identified a key mechanism of lung inflammation induced by silica exposure, ...

PET scans to optimize tuberculosis meningitis treatments and personalize care, study finds

December 6, 2018
Although relatively rare in the United States, and accounting for fewer than 5 percent of tuberculosis cases worldwide, TB of the brain—or tuberculosis meningitis (TBM)—is often deadly, always hard to treat, and a particular ...

Infectivity of different HIV-1 strains may depend on which cell receptors they target

December 6, 2018
Distinct HIV-1 strains may differ in the nature of the CCR5 molecules to which they bind, affecting which cells they can infect and their ability to enter cells, according to a study published December 6 in the open-access ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.